The Insight™ eNO System

The Insight eNO System provides accurate measurement of airway inflammation for routine application in the physician’s office

When it comes to managing asthma, there are many variables that make it difficult to know your patient’s real health. With an accurate measure of your patient’s airway inflammation, the underlying condition in asthma, you can now significantly improve the effectiveness of your therapy for asthma. With the Insight eNO System, you can now see what you have otherwise been missing with current methods of asthma management.

The Insight eNO System measures exhaled nitric oxide (eNO) which offers:

  • Accurate measure of your patient’s degree of airway inflammation 10,11,12
  • Effective method to titrate and adjust asthma medication 1
  • Clinical approach to identify lack of compliance 2,13
  • Safe monitoring and prediction of asthma control 2,3,4

Power to enhance clinical decision-making

The Insight system utilizes a patented biosensor technology to provide safe, accurate and non-invasive measurement of nitric oxide. The Insight system’s unique, simple design features:

  • A product designed exclusively for the physician's practice
  • Comprehensive data management and analysis for customized patient therapy
  • A hygienic approach that is safe for use in a multi-patient clinic setting
  • A long-lasting, reliable system proven for 18,000 test cycles between service intervals
  • Accurate measurement of nitric oxide for a broad population of asthma patients

With these features, you can spend your time with patients more efficiently and make clinical decisions more confidently. In addition, the Insight system comes with world-class customer service and product performance that lets you focus on your patient.

The Insight system has five main components:

  • A small desktop Insight monitor with a large color screen that acts as the primary user-interface
  • Non-invasive Insight sensors
  • Disposable Insight breath tubes
  • Patient-specific smart cards to record and save patients' eNO data
  • Dedicated printer to print trend charts and reports

Each system also comes with accessories for regular quality control of the system.

Indications for Use and Safety Information.

The intended use of the Apieron Insight™ eNO System is to quantitatively measure exhaled nitric oxide (eNO) in expired human breath as a marker of inflammation in persons with asthma. Measurement of eNO in expired human breath by the Apieron Insight eNO System is a non-invasive, simple and safe method to measure a decrease in eNO in asthma patients that often occurs after treatment with anti-inflammatory pharmacological therapy as an indication of the therapeutic effects in patients with elevated eNO levels.The Apieron Insight eNO System is suitable for use in children 8 to 17 years of age, and in adults 18 years of age and older. As an adjunct to established clinical assessments, eNO measurements give the physician an objective marker to evaluate the patient's response to anti-inflammatory therapy. The Apieron Insight eNO System can be used by trained operators in a physician's office or laboratory setting. The Apieron Insight eNO System should not be used in critical care, emergency care or in anesthesiology.

Federal law restricts this device to sale by or on the order of a physician.

1 Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma. N Engl J Med. 2005;352(21):2163-2173.
2 Delgado-Corcoran C, Kissoon N, Murphy SP, Duckworth LJ. Exhaled Nitric Oxide Reflects Asthma Severity and Asthma Control. Pediatr Crit Care Med. 2004;5(1):48-52.
3 Jones SL, Kittelson J, Cowan JO et al. The Predictive Value of Exhaled Nitric Oxide Measurements In Assessing Changes In Asthma Control. Am J Respir Crit Care Med. 2001;164:738-743
4 Harkins MS, Fiato KL, Iwamoto GK. Exhaled Nitric Oxide Predicts Asthma Exacerbation. Journal of Asthma. 2004;41(4):471-476
10 Frank TL, Adisesh A, Pickering AC, et al. Relationship Between Exhaled Nitric Oxide and Childhood Asthma. Am J Respir Crit Care Med. 1998;158:1032-1036
11 Sergei A, Kharitonov SA, Yates DH, Barnes PJ. Inhaled Glucocorticoids Decrease Nitric Oxide in Exhaled Air of Asthmatic Patients. Am J Resp Crit Care Med. 1996;153:454-457
12 Holgate S. Mediator and Cytokine Mechanisms in Asthma. Thorax. 1993;48:103-109
13 Beck-Ripp J, Griese M, Arenz S, et al. Changes of Exhaled Nitric Oxide During Steroid Treatment of Childhood Asthma. Eur. Respir. J. 2002;19:1015-1019.